BridgeBio Pharma Inc (NASDAQ:BBIO) reported fourth-quarter financial results that surpassed analyst revenue expectations, driven by the accelerating commercial launch of its heart drug Attruby. However, the company's net loss per share was wider than anticipated, reflecting significant investments in its expanding commercial infrastructure and late-stage pipeline.
The biopharmaceutical firm's shares were trading approximately 2.8% higher in after-hours activity following the report, suggesting investor focus on the robust revenue growth and a series of positive clinical trial readouts over recent months.
Financial Performance Versus Estimates
For the fourth quarter ended December 31, 2025, BridgeBio reported total revenue of $154.2 million, a substantial increase from $5.9 million in the prior-year period. This performance handily exceeded the consensus analyst estimate of approximately $149.8 million.
The company's net loss attributable to common stockholders was $192.9 million, or $1.00 per share. This loss was deeper than the analyst estimate for a non-GAAP loss of $0.76 per share.
Key financial highlights from the quarter include:
- Net Product Revenue: $146.0 million, primarily from U.S. sales of Attruby (acoramidis) for ATTR-CM, compared to $2.9 million in Q4 2024.
- Full-Year 2025 Revenue: $502.1 million, up from $221.9 million in 2024.
- Operating Expenses: Total operating costs and expenses were $293.7 million for the quarter, up from $231.9 million a year ago, driven by commercial investments for Attruby and pipeline advancement.
- Cash Position: The company held $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025. It bolstered its balance sheet further in January 2026 with the issuance of $632.5 million in convertible notes.
Commercial Momentum and Pipeline Catalysts
Beyond the financials, the earnings report highlighted significant commercial and clinical progress that underpins the company's growth narrative.
Attruby's Strong Launch: The commercial launch of Attruby continues to gain traction. As of February 20, 2026, 7,804 unique patient prescriptions had been written by 1,856 prescribers since the drug's FDA approval in November 2024. The company reported 35% quarter-over-quarter growth in net product revenue for Q4.
A Wave of Phase 3 Successes: BridgeBio emphasized a remarkable period of clinical execution, announcing three positive Phase 3 trial readouts in just over three months:
- BBP-418 for LGMD2I/R9: The FORTIFY trial interim analysis showed a statistically significant improvement. The FDA recommended pursuing traditional approval, supporting a planned New Drug Application (NDA) submission in the first half of 2026.
- Encaleret for ADH1: The CALIBRATE trial met all endpoints. Following a successful pre-NDA meeting with the FDA, an NDA submission is also planned for the first half of 2026.
- Infigratinib for Achondroplasia: The PROPEL 3 trial successfully met its primary endpoint, showing the first statistically significant improvements in body proportionality. An NDA submission is expected in the second half of 2026.
The company anticipates potential U.S. launches for BBP-418 and encaleret in late 2026 or early 2027, and for infigratinib in early to mid-2027. CEO Neil Kumar stated these successes could lead to six approved products by the end of the company's first decade.
Market Reaction and Forward Outlook
The positive after-market price movement indicates investors are rewarding the strong top-line beat and the clear pathway toward multiple near-term regulatory filings. The wider-than-expected loss appears to be viewed as an acceptable cost of funding this rapid transition into a commercial-stage company with a maturing pipeline.
While the press release did not provide specific quantitative financial guidance for 2026, the operational outlook is densely populated with catalysts. The company is preparing for three major NDA submissions within the next 12 months. Analyst estimates for the full year 2026 project sales of approximately $931.6 million, suggesting expectations for continued steep growth from Attruby.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can view more on BridgeBio's earnings and estimates page here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing carries risks, including the potential loss of principal.